Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination

Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination

Mai-Chi Hong1, Donald I Hsu1,2, Mark Bounthavong3,41Department of Pharmacy Practice and Administration, Western University of Health Sciences, Pomona, 2Department of Pharmacy, St Joseph Hospital, Orange, 3Department of Pharmacy, Veterans Affairs San Diego Healthcare System, San Diego, 4Department of...

Full description

Bibliographic Details
Main Authors:	Hong MC, Hsu DI, Bounthavong M
Format:	Article
Language:	English
Published:	Dove Medical Press 2013-11-01
Series:	Infection and Drug Resistance
Online Access:	http://www.dovepress.com/ceftolozanetazobactam-a-novel-antipseudomonal-cephalosporin-and-beta-l-a15132

Similar Items

A Novel β-lactam/β-lactamase Inhibitor: Ceftolozane/tazobactam
by: Kıvanç ŞEREFHANOĞLU
Published: (2019-12-01)

Ceftolozane-Tazobactam Combination Therapy Compared to Ceftolozane-Tazobactam Monotherapy for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis
by: Marco Fiore, et al.
Published: (2021-01-01)

Best practices: Appropriate use of the new β-lactam/β-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam in South Africa
by: Adrian J. Brink, et al.
Published: (2022-10-01)

Ceftolozane/Tazobactam Dosing Requirements Against Bacteremia
by: Jesus Ruiz, et al.
Published: (2020-01-01)

Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in <named-content content-type="genus-species">Pseudomonas aeruginosa</named-content>
by: Melissa D. Barnes, et al.
Published: (2018-12-01)

Comparison between meropenem and ceftolozane/tazobactam: possible influence of CRRT
by: Patrick M. Honore, et al.
Published: (2022-01-01)

Ceftolozane-tazobactam in combination with fosfomycin for treatment of MDR/XDR P. aeruginosa infective endocarditis
by: A. Prescott, et al.
Published: (2019-10-01)

Chemical Stability of Ceftolozane/Tazobactam in Polyvinylchloride Bags and Elastomeric Pumps
by: Joseph Terracciano, PhD, et al.
Published: (2017-01-01)

Piperacillin–Tazobactam Plus Vancomycin-Associated Acute Kidney Injury in Adults: Can Teicoplanin or Other Antipseudomonal Beta-Lactams Be Remedies?
by: Abdullah Tarık Aslan, et al.
Published: (2022-08-01)

Hypermutator strains of Pseudomonas aeruginosa reveal novel pathways of resistance to combinations of cephalosporin antibiotics and beta-lactamase inhibitors.
by: Augusto Dulanto Chiang, et al.
Published: (2022-11-01)

Ceftolozane/tazobactam for the treatment of bacteremia: a systematic literature review (SLR)
by: Z. S. Khankhel, et al.
Published: (2022-10-01)

Evaluation of ceftolozane-tazobactam susceptibility on a French nationwide collection of Enterobacterales
by: Agnès B. Jousset, et al.
Published: (2023-03-01)

Monotherapy of ceftazidime–avibactam and ceftolozane–tazobactam against multidrug-resistant organisms
by: Adnan Alatoom
Published: (2017-09-01)

Ceftolozane/tazobactam – the "new player" in a battle against multiresistant pathogens
by: Golub A.V., et al.
Published: (2018-11-01)

Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections
by: Goodlet KJ, et al.
Published: (2016-12-01)

Real-world use of ceftolozane/tazobactam: a systematic literature review
by: Laura Puzniak, et al.
Published: (2021-04-01)

The inhibition of metallo-beta-lactamase by thioxo-cephalosporin derivatives.
by: Tsang, W, et al.
Published: (2004)

Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections
by: Skalweit MJ
Published: (2015-06-01)

Antimicrobial activity of cephalosporin–beta-lactamase inhibitor combinations against drug-susceptible and drug-resistant Pseudomonas aeruginosa strains
by: Amani M. Alnimr, PhD, et al.
Published: (2020-06-01)

Optimizing ceftolozane-tazobactam dosage during continuous renal replacement therapy: additional insights
by: Patrick M. Honore, et al.
Published: (2019-12-01)

Optimizing Doses of Ceftolozane/Tazobactam as Monotherapy or in Combination with Amikacin to Treat Carbapenem-Resistant <i>Pseudomonas aeruginosa</i>
by: Worapong Nasomsong, et al.
Published: (2022-04-01)

Finding the Dose for Ceftolozane-Tazobactam in Critically Ill Children with and without Acute Kidney Injury
by: Laura Butragueño-Laiseca, et al.
Published: (2020-12-01)

Subgroup analysis of phase 2 study of ceftolozane/tazobactam in neonates and young infants with pyelonephritis
by: Emmanuel Roilides, et al.
Published: (2023-10-01)

In Vitro Activity of Ceftolozane/tazobactam and Ceftazidime/avibactam Against Carbapenemase-producing Pseudomonas aeruginosa
by: Özlem AYDEMİR, et al.
Published: (2019-12-01)

Cost-effectiveness of ceftolozane/tazobactam for the treatment of complicated intraabdominal and urinary tract infections in Colombia
by: Fabián Hernández
Published: (2020-02-01)

Treatment of bone and joint infections by ceftazidime/avibactam and ceftolozane/tazobactam: a cohort study
by: Claire Rempenault, et al.
Published: (2021-06-01)

Optimizing ceftolozane-tazobactam dosage in critically ill patients during continuous venovenous hemodiafiltration
by: Gerardo Aguilar, et al.
Published: (2019-04-01)

Influence of extracorporeal membrane oxygenation on the pharmacokinetics of ceftolozane/tazobactam: an ex vivo and in vivo study
by: Camille Mané, et al.
Published: (2020-05-01)

In vitro susceptibility of Burkholderia pseudomallei isolates from Thai patients to ceftolozane/tazobactam and ceftazidime/avibactam
by: Wantin Sribenjalux, et al.
Published: (2022-03-01)

Stability Studies of Antipseudomonal Beta Lactam Agents for Outpatient Therapy
by: Beatriz Fernández-Rubio, et al.
Published: (2023-11-01)

Comparative in vitro activities of seven new beta-lactams, alone and in combination with beta-lactamase inhibitors, against clinical isolates resistant to third generation cephalosporins
by: Varsha Gupta, et al.

In vitro synergistic antimicrobial activity of a combination of meropenem, colistin, tigecycline, rifampin, and ceftolozane/tazobactam against carbapenem-resistant Acinetobacter baumannii
by: Yong Guk Ju, et al.
Published: (2022-05-01)

Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant <i>Pseudomonas aeruginosa</i> Infections in Neutropenic Patients
by: Paolo E. Coppola, et al.
Published: (2020-12-01)

Ceftolozane/tazobactam for the treatment of complicated intra-abdominal and urinary tract infections: current perspectives and place in therapy
by: Escolà-Vergé L, et al.
Published: (2019-07-01)

Ceftazidime/Avibactam and Ceftolozane/Tazobactam for Multidrug-Resistant Gram Negatives in Patients with Hematological Malignancies: Current Experiences
by: Marianna Criscuolo, et al.
Published: (2020-02-01)

Whole Genome Sequencing of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Resistant Pseudomonas aeruginosa Isolated from a Blood Stream Infection Reveals VEB and Chromosomal Metallo-Beta Lactamases as Genetic Determinants: A Case Report
by: Alamri AM, et al.
Published: (2020-11-01)

Clinical and microbiological features of ceftolozane/tazobactam-resistant Pseudomonas aeruginosa isolates in a university hospital in central Italy
by: Gianluca Morroni, et al.
Published: (2022-09-01)

Tazobactam/ceftolozane and tobramycin combination therapy in extensively drug-resistant Pseudomonas aeruginosa infections in severe burn injury: a case report
by: Yuta Ibe, et al.
Published: (2023-08-01)

Evaluation of in vitro activity of ceftolozane-tazobactam in combination with other classes of antibacterial agents against Enterobacterales and Pseudomonas aeruginosa—the EM200 study
by: J. Belkhair, et al.
Published: (2021-05-01)

Ceftolozane-tazobactam and ceftazidime-avibactam activity against β-lactam-resistant Pseudomonas aeruginosa and extended-spectrum β-lactamase-producing Enterobacterales clinical isolates from U.S. medical centres
by: Elizabeth B. Hirsch, et al.
Published: (2020-09-01)